NCT07110662 - New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 29, 2025

Primary Completion Date

October 29, 2028

Study Completion Date

April 29, 2029

Conditions

Toxic Epidermal NecrolysisImmunotherapyCutaneous Adverse Drug Reactions (CADR)

Interventions

DRUG

DARATUMUMAB (DARZALEX®)

A single injection of DARZALEX 16 mg/kg body weight administered by intravenous infusion (day 1) in addition to standard symptomatic treatment of NET until re-epidermalization.

Trial Locations (1)

69437

Reference Center for Toxic, Toxin and Toxidermal Bullous Dermatoses - E. Herriot Hospital, Lyon

All Listed Sponsors

collaborator

Janssen-Cilag Ltd.

INDUSTRY

collaborator

INSERM U1111

UNKNOWN

lead

Hospices Civils de Lyon

OTHER